Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:33:36.249Z.
Calculation as of: 2026-10-06T20:33:36.249Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3fd66fa07f89ff8c2236b8eda0ba832ed38a6b1a46891be7cbf8760d0061f77
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$667469.00
PS Ratio
N/A
TTM Avg
18343.16
3Y Avg
32993.59
5Y Avg
90981.83
Market Cap
$824550.00
PS Ratio
N/A
TTM Avg
86.14
3Y Avg
51.38
5Y Avg
839.91
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $481786.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | 4.63 | 17.12 | 18.70 | 18.70 |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | 0.08 | 5.16 | 225.96 | 406.71 |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | N/A | 18343.16 | 32993.59 | 90981.83 |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | N/A | 86.14 | 51.38 | 839.91 |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-17 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-19 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-17 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
